Illumina provides an innovative portfolio of next-generation sequencing (NGS) systems, products, and services for the drug development pipeline. With solutions to inform the drug development process, you can confidently choose us as a partner from discovery through companion diagnostics development.
NGS approaches can generate multiple levels of genomic data essential for drug development, from genomic modifications to transcriptome profiling and quantification, epigenetic modifications, and more.
We are uniquely positioned to deliver products and services to support pharmaceutical development with the largest install base of NGS instrumentation.
Approximately 90 percent of all sequencing data produced today has been generated using Illumina technologies*. Reference and service labs are installing our instruments in increasing numbers to perform a wide variety of applications.
The Illumina portfolio informs multiple stages of the drug discovery and pharmaceutical development process, from target identification to post approval.
Click on the below to view methods and products supporting the various drug discovery and development stages.
Take a comprehensive view of the genomic variation linked to a pathway.
Whole-Exome SequencingExplore genomic variation in the protein-coding regions of the genome as a cost-effective alternative to WGS.
RNA SequencingCharacterize expression by sequencing individual targets or the entire transcriptome.
Cancer Sequencing MethodsPerform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Immuno-Oncology ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Learn how to use RNA-Seq to identify novel RNA-based drug response biomarkers.
EpigeneticsFind NGS and microarray tools to study epigenetic modifications and their impact on gene regulation.
Sequencing PlatformsFind the sequencing system that best fits your scale of study.
Bioinformatics ToolsUser-friendly tools to guide you from experimental design to data interpretation and reporting.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Or leverage RNA-Seq to discover and profile RNA-based drug response biomarkers.
Immuno-Oncology ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment
Find the sequencing system that best fits your scale of study.
InformaticsUser-friendly tools guide you from experimental design to data interpretation and reporting.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Or leverage RNA-Seq to discover and profile drug response RNA biomarkers.
Immuno-Oncology ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Find the sequencer that best fits your scale of study.
InformaticsUser-friendly tools guide you from experimental design to data interpretation and reporting.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Explore our unique, multi-analyte approach to co-development.
Cancer Sequencing MethodsPerform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.
TruSight Oncology 500 Product FamilyEnabling comprehensive genomic profiling from both blood and tissue samples.
Cancer RNA SequencingConfirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples.
Immuno-Oncology ResearchNGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.
Find the sequencer that best fits your scale of study.
Companion Diagnostics DevelopmentExplore our unique, multi-analyte approach to co-development.
High-Throughput Genotyping Research ToolsGain meaningful insights from complex populations.
InformaticsUser-friendly tools guide you from experimental design to data interpretation and reporting.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Explore our unique, multi-analyte approach to co-development.
MiSeqDx InstrumentDiscover the first FDA-cleared next-generation sequencing system.
NextSeq 550Dx InstrumentExplore the next level in diagnostic power for the clinical lab.
Gain meaningful insights from complex populations.
Genomic ServicesFind an Illumina service provider to support your genomics needs.
Integrating imaging, multiomic technologies, and big data uncovers novel diagnostic and therapeutic targets for common chronic diseases.
Read InterviewResearchers utilize transcriptomics to uncover multiple drug-susceptible tumorigenic pathways.
Read InterviewWhole-genome shotgun sequencing and transcriptomics provide pharmaceutical scientists with data to refine drug discovery and development.
Read InterviewDr. Jeffrey Conroy, Chief Scientific Officer of OmniSeq, Inc., discusses the value of combining genomic and immune profiling. He also showcases the impact of a scalable comprehensive assay and infrastructure in the context of drug development.
View WebinarNGS-based methods allow cancer researchers to detect rare somatic variants, tumor subclones, and circulating DNA fragments. Learn more about cancer genomics.
From metagenomics and microbiome studies to infectious disease surveillance, NGS can help researchers gain genetic insight into bacteria and viruses. Learn more about microbial genomics.
Sequencing is introducing new avenues for understanding autoimmune diseases, atherosclerosis, neurological diseases, and psychiatric disorders on a molecular level. Learn more about complex disease genomics.
NGS can help scientists uncover genetic variants associated with rare and undiagnosed disorders. Learn more about rare disease genomics.
* Data calculations on file. Illumina, Inc. 2017.